This page shows what was measured, who it was measured in, and what that does not settle.
What Prednisone does in the body
The short steroid course — for an asthma attack, a bad flare-up, a severe allergic reaction
Prednisone does nothing at all until the liver changes one atom on it, turning it into prednisolone. That version slips through cell membranes, finds a receptor waiting in the cytoplasm, and carries it into the nucleus, where it sits on DNA and rewrites which genes the cell is running. Dozens of inflammatory genes are switched off and a handful of calming ones are switched on. Nothing about that process is targeted: every cell with the receptor gets the same instruction, which is why the drug works so well and costs so much.
What happened in people
Relapse after an asthma exacerbation RR 0.38 (95% CI 0.20 to 0.74) in the first week, hospitalisation RR 0.35 (0.13 to 0.95)
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
The strongest argument for inhaled corticosteroids in asthma is not that they work better; it is that they reduce how often this drug is needed
Where it acts
Cytoplasmic glucocorticoid receptors in almost every nucleated cell in the body. The drug is inert until the liver converts it, and once converted it acts everywhere.
Kind of result
The kind of result is not recorded
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · VB0R961HZT · read 2026-08-29
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 137 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Receptor
A receptor is a part of a cell that a signal fits into.
A picture of it, and where the picture fails
A receptor is like a lock waiting for one key.
Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.
What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.
A protein that binds a specific ligand and converts that binding into a cellular response.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Time to next exacerbation within 180 days, 5 days against 14 days of prednisone 40 mg daily in acute COPD exacerbation
Hazard ratio 0.95 (90% CI 0.70 to 1.29), p=0.006 for non-inferiority intention-to-treat; re-exacerbation 37.2% against 38.4%, difference -1.2% (95% CI -12.2% to 9.8%); cumulative prednisone 379 mg against 793 mg, p<0.001
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Hyperglycaemia and hypertension did not differ between arms. A 314-patient trial is not powered to detect the 30-day sepsis, thromboembolism and fracture excesses measured in a 1.5-million-person cohort, so this is an absence of detection rather than an absence of harm.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
Interval reported. 95% CI -12
Written into the record, not signed off as a reviewed claim.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Oral prednisone did not differ from placebo on any visual measure; new episodes of optic neuritis in either eye were more frequent on oral prednisone than placebo, relative risk 1.79 (95% CI 1.08 to 2.95)
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. The harm signal was in the primary publication and reached the Precautions section of the label. It never reached the Indications section, which still names optic neuritis among the ophthalmic conditions the drug is indicated for.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
Interval reported. 95% CI 1
Written into the record, not signed off as a reviewed claim.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Relapse requiring additional care within one week of discharge
✓ The study showed what it set out to show
Who was studied
Cochrane corticosteroids for preventing relapse after acute asthma (CD000195.pub2)
How many people
374
Study design
Systematic review and meta-analysis of 6 randomised trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
RR 0.38 (95% CI 0.20 to 0.74) at one week; RR 0.47 (95% CI 0.25 to 0.89) at 21 days; hospitalisation RR 0.35 (95% CI 0.13 to 0.95); number needed to treat about 10
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Only 374 people across six trials, with side effects rarely reported and statistically heterogeneous where they were. The benefit estimate is robust; the safety estimate from these trials is close to uninformative.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Outpatient admissions by days 1 and 7, and inpatient length of stay, in children under 24 months
✗ The study did not show it
Who was studied
Cochrane glucocorticoids for acute viral bronchiolitis (CD004878.pub4)
How many people
2596
Study design
Systematic review and meta-analysis of 17 randomised trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Admissions day 1 RR 0.92 (95% CI 0.78 to 1.08); day 7 RR 0.86 (95% CI 0.70 to 1.06); length of stay mean difference -0.18 days (95% CI -0.39 to 0.04)
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Baseline severity, steroid regimens, comparators and outcomes were heterogeneous, and only three of 17 trials had low overall risk of bias. A combined dexamethasone plus inhaled epinephrine result from one factorial trial was unadjusted and the reviewers did not treat it as practice-changing.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Incidence rate ratios for sepsis, venous thromboembolism and fracture within 30 days of starting an oral corticosteroid course of under 30 days
✓ The study showed what it set out to show
Who was studied
Waljee et al. United States short-course corticosteroid cohort and self-controlled case series (BMJ 2017;357:j1415)
How many people
1548945
Study design
Retrospective cohort with self-controlled case series, nationwide insurance claims
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Sepsis IRR 5.30 (95% CI 3.80 to 7.41); venous thromboembolism 3.33 (2.78 to 3.99); fracture 1.87 (1.69 to 2.07); persisting below 20 mg/day prednisone equivalent at 4.02, 3.61 and 1.83, all p<0.001
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The self-controlled design removes stable between-person confounding but not the acute illness that prompted the prescription, which sits inside the same 30-day risk window. The finding that 21.1% of a working-age insured population received a course over three years is not confounded by anything.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
Interval reported. 95% CI 3
Written into the record, not signed off as a reviewed claim.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
RNAWiki holds 5 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.17 registered measures of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
□A number that stands in for healthNo evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.No registered study measures this.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in C. elegans (roundworm), Mouse, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Where a source records it acting
Adrenal glands: Pharmacologic corticosteroid dosing interacts with hypothalamic-pituitary-adrenal (HPA) activity; the label discusses dosing regimens intended to minimize pituitary-adrenal suppression
US prescribing information · 0060b86b-0b79-4c54-a7be-97683a933a05 · read 2026-08-27
Start
Prednisone
What a person takes: Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation.
The measurement behind this step
Readily absorbed from the gastrointestinal tract, then converted in the liver to prednisolone, which is the active molecule. The label describes prednisone as very slightly soluble in water and supplied as the monohydrate. Metabolic clearance is decreased in hypothyroid patients and increased in hyperthyroid patients, and the label warns of an enhanced effect due to decreased metabolism in cirrhosis — so the same tablet is a different exposure in different people.
Getting in
The tablet is inactive
What you swallow does not fit the receptor. It is a prodrug, and until the liver changes it, nothing happens.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Prednisone carries a ketone at C11. The glucocorticoid receptor requires an 11-beta-hydroxyl. The label’s own chemical name, pregna-1,4-diene-3,11,20-trione 17,21-dihydroxy- monohydrate, names the C11 ketone that has to be reduced before the molecule has any activity at all.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
An enzyme in liver cells reduces one ketone to an alcohol. That single change turns prednisone into prednisolone, which is the drug that works.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
11-beta-hydroxysteroid dehydrogenase type 1 catalyses the NADPH-dependent reduction of the C11 ketone. The measurement that matters in any pharmacokinetic study is therefore prednisolone, not prednisone. The label warns of an enhanced effect due to decreased metabolism of corticosteroids in cirrhosis, and of altered clearance in thyroid disease in both directions.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Unlike most drug targets, this receptor is not on the cell surface. Prednisolone passes straight through the membrane and binds it in the cytoplasm.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The glucocorticoid receptor, NR3C1, sits in the cytoplasm in a chaperone complex. Ligand binding releases the chaperones and exposes the nuclear localisation signal. Almost every nucleated cell in the body carries this receptor, which is why nothing about a systemic glucocorticoid is tissue-selective.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
The receptor carries the drug into the nucleus and sits on DNA, switching dozens of inflammatory genes off and a few calming ones on.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The ligand-bound receptor translocates to the nucleus and both activates transcription at glucocorticoid response elements and represses inflammatory transcription driven by NF-kappaB and AP-1. The prednisone label describes this only in the most general terms available in 1955 language: glucocorticoids cause profound and varied metabolic effects, and modify the body’s immune responses to diverse stimuli.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
Over hours to a day the swelling in the airway subsides, and the chance of coming back for more treatment falls by more than half.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Relapse to additional care within one week after an asthma exacerbation: RR 0.38 (95% CI 0.20 to 0.74), sustained to 21 days at RR 0.47, with subsequent hospitalisation RR 0.35. In COPD, five days of 40 mg was non-inferior to fourteen on time to next exacerbation over 180 days (HR 0.95, 90% CI 0.70 to 1.29).
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
The same instruction reaches bone, blood sugar, the immune system and the adrenal gland. In the thirty days after a course, sepsis, clots and fractures are all measurably more common.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Within 30 days of a short course: sepsis IRR 5.30 (95% CI 3.80 to 7.41), venous thromboembolism 3.33 (2.78 to 3.99), fracture 1.87 (1.69 to 2.07), persisting below 20 mg/day prednisone equivalent. Adrenal insufficiency after cessation ranges from 1.4% after under 28 days to 27.4% after more than a year of asthma treatment, and the label states relative insufficiency may persist for 12 months.
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 6 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
No registered study measured anything of this kind.
Meaningful
Things that change how a life goes, not only a number.
progression free survival
overall survival
survival
event free survival
complete remission
event free survival after first randomization
disease free survival after second and third randomization
2 year overall survival rates
2 year progression free survival
disease free survival
and 7 more.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (23)
overall response
complete response
clinical response
response
feasibility of intensification
time to treatment failure
complete or partial response to treatment mtx
response to treatment
time to failure
response rate
immune response
adverse events
objective response rate for treatment arm
incidence of drop out or dose reduction
toxicity
responders
complete response rate
efficacy
duration of response
engraftment
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
One in five insured American adults received at least one short outpatient course over three years, most often for upper respiratory infections, spinal conditions and allergies — indications that are largely not on the label.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The efficacy and safety of prednisone in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations.”
US prescribing information · 474974ac-9811-c9f5-4050-58e535351d00 · read 2026-08-30
On older people, the label states: “No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience with prednisone has not identified differences in responses between the elderly and younger patients.”
US prescribing information · 474974ac-9811-c9f5-4050-58e535351d00 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on findings from human and animal studies, corticosteroids, including prednisone delayed-release tablets, can cause fetal harm when administered to a pregnant woman (see Data ) [see Warnings and Precautions (5.10) ] .”
US prescribing information · 474974ac-9811-c9f5-4050-58e535351d00 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Prednisolone has been found to be present in human milk following administration to lactating women.”
US prescribing information · 474974ac-9811-c9f5-4050-58e535351d00 · read 2026-08-30
Where the result stopped carrying
Oral prednisone in acute optic neuritis: ineffective, and it raised the rate of new episodes
Glucocorticoids in infant bronchiolitis: no effect on admissions at day 1 or day 7, no effect on length of stay
The 7-to-14-day COPD course, which REDUCE showed was twice as much drug as the job required
Adrenal recovery, which the label concedes may take up to 12 months and which pooled testing finds incomplete in a quarter of long-term users
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Readily absorbed from the gastrointestinal tract, then converted in the liver to prednisolone, which is the active molecule. The label describes prednisone as very slightly soluble in water and supplied as the monohydrate.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold. The rest of the recorded wording: Metabolic clearance is decreased in hypothyroid patients and increased in hyperthyroid patients, and the label warns of an enhanced effect due to decreased metabolism in cirrhosis — so the same tablet is a different exposure in different people.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
The adverse reaction list runs across every organ system. Immunosuppression with increased risk of any infection, masking of the signs of infection, and severe or fatal outcomes at higher doses; specific hazards include tuberculosis reactivation, Strongyloides hyperinfection with potentially fatal gram-negative septicaemia, and serious or fatal varicella and measles in non-immune patients. Hypothalamic-pituitary-adrenal suppression that may persist up to 12 months after stopping, with a named withdrawal syndrome of myalgia, arthralgia and malaise. Decreased bone formation and increased resorption at any age, and growth suppression in children at low systemic doses even without laboratory evidence of axis suppression. Psychic derangements from euphoria and insomnia through mood swings and severe depression to frank psychosis. Posterior subcapsular cataract, glaucoma with possible optic nerve damage, and raised intraocular pressure requiring monitoring beyond six weeks. Sodium and water retention, potassium loss, hypertension, hyperglycaemia and new or unmasked diabetes. Diminished response to vaccines, and potentiated replication of organisms in live attenuated vaccines. An apparent association with left ventricular free wall rupture after recent myocardial infarction.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
Where this came from
Prednisone tablets United States prescribing information — Description, Clinical Pharmacology, Indications and Usage (all ten categories), Warnings (Cardio-R… · a recorded source, not a stored snapshot
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Prednisone appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 22755 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral tablets at 1, 2.5, 5, 10 and 20 mg, plus an oral solution and a delayed-release tablet formulation
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
The label describes prednisone as very slightly soluble in water and supplied as the monohydrate.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold. The rest of the recorded wording: Metabolic clearance is decreased in hypothyroid patients and increased in hyperthyroid patients, and the label warns of an enhanced effect due to decreased metabolism in cirrhosis — so the same tablet is a different exposure in different people.
No source is stored against this line.
What is recorded as being sold
325 products list this as an active ingredient in the United States drug directory. 325 of them contain it and nothing else.
FDA National Drug Code directory · 71335-3042 · read 2026-08-29
They are sold as powder, solution, solution, concentrate, tablet and tablet, delayed release, taken oral.
FDA National Drug Code directory · 71335-3042 · read 2026-08-29
The regulator's established pharmacologic class for it is corticosteroid hormone receptor agonists [moa] and corticosteroid [epc].
FDA National Drug Code directory · 71335-3042 · read 2026-08-29
248 published labels name it as an active ingredient. 248 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 7ea7f6a9-78ef-42fe-baac-f817da3976fb · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 7ea7f6a9-78ef-42fe-baac-f817da3976fb · read 2026-08-29
56 marketed supplement labels list this ingredient, classed as non-nutrient/non-botanical and other combinations.
Those labels carry all other and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.
Recorded price in US: 0.0367–0.57318 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 115 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 0.44318–0.60788 USD per one millilitre, across 2 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Prednisone studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That everything on the ten-category indication list has been shown to work — most of it predates the 1962 requirement for substantial evidence of effectiveness and has no modern randomised support
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a short course is a low-risk intervention, when the 30-day harm rates persist below 20 mg/day prednisone equivalent
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That prednisolone must replace prednisone in liver disease, an inference from the prodrug step rather than a demonstrated clinical failure — and one the label’s cirrhosis warning about enhanced effect does not support
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the absence of a detected adverse-event difference in a 314-patient or 374-patient trial says anything about the harms measured in cohorts a thousand times larger
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
How fast does the body clear it?
The sources RNAWiki checked hold nothing for this field.
Why it matters. Without this, nothing on this page can say how long anything lasts.
What would answer it
A stored source that records it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Prednisone are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
The label lists optic neuritis as an indication and tells you not to use it there
In plain words
Section 6 of the prescribing information names optic neuritis among the eye conditions prednisone is indicated for. The precautions section of the same document says oral corticosteroids are not recommended in optic neuritis and may increase the risk of new episodes. Both sentences are in the label a pharmacist dispenses against today.
What was measured
Rate of new optic neuritis episodes on oral prednisone against placebo, and the indication text that survived it
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The Optic Neuritis Treatment Trial randomised 457 patients with acute optic neuritis at 15 centres to oral prednisone 1 mg/kg/day for 14 days, intravenous methylprednisolone 1 g/day for 3 days followed by oral prednisone, or oral placebo. The outcome in the oral-prednisone group did not differ from placebo on any visual measure. The rate of new episodes of optic neuritis in either eye was higher on oral prednisone than on placebo — relative risk 1.79 (95% CI 1.08 to 2.95) — and was not raised in the intravenous methylprednisolone group. The authors concluded that oral prednisone alone as prescribed in that study is an ineffective treatment and increases the risk of new episodes. That finding was published in 1992 and is reflected in the Precautions: Ophthalmic paragraph of the current label, which states that the use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. It was never removed from the indications list in section 6. This is what a label looks like when there is no innovator sponsor left to revise it.
Written into the record, not signed off as a reviewed claim
After an asthma attack it more than halves the relapse rate
In plain words
Six randomised trials followed people sent home from emergency departments after an asthma attack. Those given a short steroid course came back for more care less than half as often, and about one in ten treated avoided a relapse that would otherwise have happened.
What was measured
Relapse requiring additional care within 7 and 21 days of discharge, and subsequent hospitalisation
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The Cochrane review of corticosteroids for preventing relapse after acute asthma exacerbations included six trials in 374 people — five oral, one intramuscular — comparing a corticosteroid course against placebo after discharge from acute care. Relapse requiring additional care in the first week: RR 0.38 (95% CI 0.20 to 0.74). Maintained over 21 days: RR 0.47 (95% CI 0.25 to 0.89). Subsequent hospitalisations: RR 0.35 (95% CI 0.13 to 0.95). Reliever use fell by a mean 3.3 activations per day (95% CI -5.6 to -1.0). The reviewers put the number needed to treat at about ten. Lung function tests and side effects in the first 7 to 10 days showed no significant difference between groups, though side-effect reporting was sparse and statistically heterogeneous, so absence of a detected difference over ten days is not evidence of safety over ten years.
Written into the record, not signed off as a reviewed claim
Five days does the work of fourteen
In plain words
Guidelines said seven to fourteen days for a COPD flare-up. A randomised trial gave 314 patients either five days or fourteen and found no difference in what happened over the next six months, at half the total steroid.
What was measured
Time to next COPD exacerbation within 180 days, 5-day against 14-day course
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
REDUCE randomised 314 patients presenting to emergency departments in five Swiss teaching hospitals with an acute COPD exacerbation — past or present smokers with at least 20 pack-years and no asthma history — to 40 mg of prednisone daily for either 5 or 14 days, placebo-controlled and double-blind. Ninety-two per cent were admitted. The primary endpoint, time to next exacerbation within 180 days, gave a hazard ratio of 0.95 (90% CI 0.70 to 1.29, p=0.006 for non-inferiority) in the intention-to-treat analysis and 0.93 (90% CI 0.68 to 1.26, p=0.005) per protocol. Re-exacerbation within 180 days was 37.2% against 38.4%, a difference of -1.2% (95% CI -12.2% to 9.8%). There was no difference in time to death, in the combined endpoint, or in recovery of lung function. Mean cumulative prednisone dose was 379 mg (95% CI 311 to 446) against 793 mg (710 to 876), p<0.001. Treatment-associated adverse reactions including hyperglycaemia and hypertension did not differ — which, given the 30-day harm rates measured elsewhere, says more about the power of a 314-patient trial to detect them than about their absence.
Written into the record, not signed off as a reviewed claim
One in five adults gets a course, and the first month afterwards is measurably worse
In plain words
A nationwide claims study followed one and a half million adults. Twenty-one per cent got at least one short steroid course in three years — most often for a chest infection, a bad back or an allergy — and in the thirty days after starting it their rate of sepsis was five times higher, blood clots three times, and fractures nearly twice.
What was measured
Incidence rate ratios for sepsis, venous thromboembolism and fracture within 30 days of starting a course of under 30 days
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Waljee and colleagues studied 1,548,945 privately insured United States adults aged 18 to 64 continuously enrolled from 2012 to 2014, using both a cohort design and a self-controlled case series so that each person acted as their own control. 327,452 (21.1%) received at least one outpatient prescription for a course of under 30 days. The commonest indications were upper respiratory tract infections, spinal conditions and allergies. Within 30 days of initiation, incidence rate ratios were 5.30 (95% CI 3.80 to 7.41) for sepsis, 3.33 (2.78 to 3.99) for venous thromboembolism and 1.87 (1.69 to 2.07) for fracture, diminishing over days 31 to 90. The elevation persisted below 20 mg/day prednisone equivalent: 4.02 for sepsis, 3.61 for venous thromboembolism, 1.83 for fracture, all p<0.001. Set that against the label, which limits the allergic-states indication to severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment, and does not list upper respiratory infection or back pain anywhere at all. The self-controlled design substantially blunts the obvious objection — that sicker people get steroids — without eliminating confounding by indication, because the illness that prompted the prescription is itself concentrated in the same 30-day window.
Written into the record, not signed off as a reviewed claim
In infant bronchiolitis it does nothing
In plain words
Seventeen trials in nearly 2,600 wheezing babies found steroids did not reduce admissions on day one or day seven, and did not shorten hospital stays.
What was measured
Outpatient admissions by days 1 and 7, and inpatient length of stay, glucocorticoid against placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The Cochrane review of glucocorticoids for acute viral bronchiolitis in children under 24 months included 17 trials with 2,596 participants, of which three had low overall risk of bias. Glucocorticoids did not significantly reduce outpatient admissions by day 1 (pooled RR 0.92, 95% CI 0.78 to 1.08) or by day 7 (RR 0.86, 95% CI 0.70 to 1.06), and produced no benefit in inpatient length of stay (mean difference -0.18 days, 95% CI -0.39 to 0.04). One large low-risk factorial trial found an unadjusted reduction in day-7 admissions with combined high-dose systemic dexamethasone plus inhaled epinephrine (RR 0.65, 95% CI 0.44 to 0.95, number needed to treat 11), a combination result the reviewers flagged as needing replication rather than adoption. This is the same population in which albuterol also fails, and for the same reason: the obstruction in bronchiolitis is shed epithelium, oedema and mucus plugging in very small airways, and neither relaxing smooth muscle nor suppressing transcription clears a plug in the time available.
Written into the record, not signed off as a reviewed claim
There is no dose or duration at which adrenal suppression can be ruled out
In plain words
Pooled testing across seventy-four studies found the adrenal glands still switched off in a substantial minority of people after stopping — 1.4% after courses under four weeks, 27.4% after more than a year, and 6.8% in people taking only an inhaled steroid.
What was measured
Pooled percentage of corticosteroid users with biochemically confirmed adrenal insufficiency, by route, dose and duration
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The systematic review and meta-analysis of adrenal insufficiency in corticosteroid users pooled 74 articles and 3,753 adult participants tested after treatment. By route, percentages ran from 4.2% for nasal administration (95% CI 0.5 to 28.9) to 52.2% for intra-articular (95% CI 40.5 to 63.6). By dose, from 2.4% at low dose (95% CI 0.6 to 9.3) to 21.5% at high dose (95% CI 12.0 to 35.5). By duration in asthma patients, from 1.4% under 28 days (95% CI 0.3 to 7.4) to 27.4% beyond a year (95% CI 17.7 to 39.8). Asthma treated with inhaled corticosteroids only still produced 6.8% (95% CI 3.8 to 12.0). The authors concluded there is no administration form, dose, duration or underlying disease for which adrenal insufficiency can be excluded with certainty, and that the threshold to test should be low. The label’s corresponding statement is that relative insufficiency may persist for up to 12 months after discontinuation and that hormone therapy should be reinstituted during any stress in that window.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A glucocorticoid prodrug that cut relapse after an asthma exacerbation by more than half (RR 0.38, 95% CI 0.20 to 0.74) and whose short courses carry a 5.30-fold rate of sepsis, 3.33-fold venous thromboembolism and 1.87-fold fracture in the first 30 days — on a 1955 label that still lists optic neuritis as an indication in section 6 while its own precautions state oral corticosteroids are not recommended for optic neuritis and may increase the risk of new episodes.
Recorded evidence blocks (12)
Q2
What did Prednisone's largest trial (6000000 people) and its longest (31 years) measure?
6000000 people in Prednisone's largest registered study, 31 years in its longest registered window, measuring Median survival. ClinicalTrials.gov · 2026-09-01
891 phase2, 545 phase3, 312 phase4, 309 phase1, 215 na, 55 na or unstated, 24 early phase1; NCT00001337; 2024-05-24; no ageing endpoint recorded. Last human test completed 2026, NCT06919458.
Interpretation These counts include studies where Prednisone was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
891
phase3
545
phase4
312
phase1
309
na
215
na or unstated
55
2 more recorded rows
early phase1
24
Last recorded human testNCT06919458
2026-08-15
recorded 2026-09-01 · last checked 2026-09-04
Q3
From C. elegans to human: where has Prednisone shown lifespan?
terminated; "Effective August 13, 2004: Unanticipated high incidence of post-transplant lymphoproliferative disorder"
NCT00024167
terminated; "Terminated due to slow accrual"
NCT00034528
terminated; "Due to slow recruitment"
14 further recorded trials
NCT00035958
terminated; "Incorporating the recommendations of the NIH-formed DSMB in the study procedures would make the project budget over the limit for this funding mechanism."
NCT00060346
terminated; "slow accrual"
NCT00060385
terminated; "low accrual"
NCT00074490
terminated; "Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2"
NCT00110006
withdrawn; "No accrual"
NCT00133172
terminated; "Varience of supply chain from that required by protocol"
NCT00135499
terminated; "Recruitment too low"
NCT00203047
terminated; "Slow enrollment decreased sample size; No unexpected safety issues."
NCT00230035
withdrawn; "Recommended by DSMB due to lack of accrual"
NCT00275106
terminated; "Withdrawn due to an excess of toxic deaths"
NCT00293371
terminated; "low accrual"
NCT00306670
terminated; "Sponsor no longer funding study."
NCT00308113
terminated; "New enrollment has been suspended, currently following previously enrolled participants"
NCT00311311
terminated; "See termination reason in detailed description."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Prednisone used 2.7 mg prednisolone plus 90 mg dipyridamole — over how long?
20 recorded entries; human; IV, tablet; also "2.7 mg prednisolone plus 90 mg dipyridamole", "2.7 mg prednisolone", "2.7 mg prednisolone plus 360 mg dipyridamole"
Show the evidence
human
NCT00521989
2.7 mg prednisolone plus 90 mg dipyridamole
NCT00521989
2.7 mg prednisolone
NCT00521989
2.7 mg prednisolone plus 360 mg dipyridamole
NCT00550550
Prednisone 5 mg Rescue Treatment
NCT00551707
prednisolone 2.7 mg plus dipyridamole 180 mg
NCT00551707
Prednisolone 2.7 mg plus Dipyridamole 360 mg
14 more recorded rows
humanNCT00562159
Prednisone 5 mg
humanNCT00632554
prednisolone 0.5 mg/kg/day for three months
humanNCT00632554
prednisolone 0.5 mg/kg/day for six months
humanNCT00657774
Oral Prednisone 10mg
humanNCT00721552
Prednisolone 30 mg
humanNCT00746512
Prednisone 15 mg
humanNCT00746512
Prednisone 7.5 mg
humanNCT01244334
Prednisolone acetate 1%
humanNCT01437982
Prednisolone Acetate 1% Oph Susp
humanNCT01782859
1. 20 mg prednisone pill to be taken in the morning of surgery prior to arrival to the hospital
humanNCT01782859
IV; 2. 100 mg hydrocortisone IV 8 hours after first dose of prednisone followed by
humanNCT01782859
tablet; Lactose filler to mimic 20 mg prednisone tablet
humanNCT01933724
5 mg prednisone
humanNCT01933724
5 mg/day prednisone
recorded 2026-09-01 · last checked 2026-09-04
Q6
Which of 2 year overall survival rates, 2 year progression free survival and adverse events did Prednisone's trials measure?
2 year overall survival rates, 2 year progression free survival and adverse events lead 40 outcome terms across Prednisone's trials. ClinicalTrials.gov · 2026-09-01
Interpretation overall survival, clinical response, survival, response, event free survival and feasibility of intensification follow.
Show the evidence
overall response
1
progression free survival
1
complete response
1
overall survival
1
clinical response
1
survival
1
14 more recorded rows
response
1
event free survival
1
feasibility of intensification
1
complete remission
1
time to treatment failure
1
event free survival after first randomization
1
disease free survival after second and third randomization
1
complete or partial response to treatment mtx
1
2 year overall survival rates
1
2 year progression free survival
1
disease free survival
1
response to treatment
1
time to failure
1
response rate
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Prednisone's 432 ongoing trials reports first?
Benefit of adjuvant involved field RT after entering complete remission with MOPP/ABV hybrid CT; Relapse-free rate; latest 2039-11-15
Show the evidence
Trial
NCT00002462
"RT or No RT Following Chemotherapy in Treating Patients With Stage III/IV Hodgkin's Disease"; n 615; "Benefit of adjuvant involved field RT after entering complete remission with MOPP/ABV hybrid CT"
NCT00005584
"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma"; n 1649; "Relapse-free rate"
NCT00092222
"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity"; n 75; "Describe natural history"; 2026-10-01
NCT00268476
"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"; n 11992; "Overall survival"; 2030-12
NCT00379041
"Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma"; n 1158; "Overall survival"
NCT00501826
"Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"; n 160; "Complete remission rate"; 2026-10-31
14 further recorded trials
NCT00555607
"Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease"; n 233; "Number of exacerbations"; 2026-12
NCT00576069
"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma"; n 60; "use exhaled nitric oxide as a surrogate marker of large airway vs small airway/lung inflammation following various doses of inhaled corticosteroids"; 2027-06
NCT00602641
"Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma"; n 306; "Progression-Free Survival (PFS)"; 2027-02-20
NCT00716066
"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases"; n 53; "Incidence of grades 4-5 regimen-related toxicity"; 2030-01-31
NCT00792948
"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia"; n 97; "Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation"; 2027-01-06
NCT00972478
"Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma"; n 83; "Safe Dose of Vorinostat to be Used in Combination With R-CHOP Assessed by CTCAE Version 4.0 (Phase I)"; 2027-03-06
NCT01046825
"Mature B-Cell Lymphoma And Leukemia Study III"; n 128; "Gene Differential Expression Profiling of Burkitt Lymphoma (BL) vs. Non-BL in the US and Other Selected Geographic Regions of the World"; 2027-08
NCT01059786
"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia"; n 69; "Number of Participants Receiving Pentostatin + Rituximab and Bendamustine + Rituximab Who Achieve a Complete Remission (CR) + Partial Response (PR)"; 2031-06-30
NCT01371630
"Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia"; n 276; "Maximum tolerated dose of inotuzumab ozogamicin based on incidence of dose limiting toxicities (Phase I)"; 2027-12-25
NCT01424982
"Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia"; n 88; "Event-free survival"; 2027-10-31
NCT01786265
"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer"; n 310; "Prostate-specific antigen (PSA) free survival (PSA < 0.1 ng/ml)"; 2027-02-01
NCT01829958
"Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy"; n 201; "Toxicity Assessment"; 2027-04
NCT01856192
"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma"; n 349; "3-year Progression-free Survival Rate"; 2026-12-31
NCT01920737
"A Novel "Pediatric-Inspired" Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia"; n 39; "rate of molecular remission"; 2026-08
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Prednisone could settle lifespan?
NCT06751108 measures Overall survival, reading out 2025-06-30.
95 open trials; n 2000; "Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients"
Show the evidence
Trial
NCT06751108
"Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients"; n 2000; "Overall survival"; 2025-06-30
NCT06789315
"Randomized Controlled Trial of Mycophenolate Mofetil Versus Steroid Therapy in Alcoholic Hepatitis"; n 60; "To compare the efficacy of MMF versus steroid therapy in improving short-term (28 day) survival outcomes in patients with alcoholic hepatitis"; 2026-01-31
NCT04951986
"Testing New Strategies for Patients Hospitalised With HIV-associated Disseminated Tuberculosis"; n 732; "All-cause mortality"; 2026-03
NCT02205762
"LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis"; n 1400; "Percentage of Patients with Reactivation Free Survival"; 2026-07
NCT04594798
"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL"; n 39; "Progression Free Survival"; 2026-07-31
NCT05901519
"A Pilot Study of Liver Protection Using Prednisone for Patients Receiving Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma"; n 20; "Mitigation of liver inflammation as reflected by sTNFR1 levels"; 2026-08
14 further recorded trials
NCT02166463
"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma"; n 600; "Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death"; 2026-10-03
NCT04446117
"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC"; n 575; "Duration of Progression Free Survival (PFS) Per Response Evaluable Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Radiology Committee (BIRC)"; 2026-10-16
NCT02877303
"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia"; n 80; "Relapse-free survival (RFS)"; 2026-11-01
NCT03706365
"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer"; n 393; "Radiographic Progression Free Survival (rPFS)"; 2026-12
NCT05850546
"Rituximab in the First Episode of Paediatric Nephrotic Syndrome"; n 138; "1-year relapse-free survival rate"; 2026-12-28
NCT05506410
"A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma"; n 100; "progression free survival（PFS）"; 2026-12-30
NCT01856192
"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma"; n 349; "3-year Progression-free Survival Rate"; 2026-12-31
NCT03749018
"Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma"; n 30; "Progression-free survival (PFS)"; 2026-12-31
NCT04216524
"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm"; n 40; "Progression free survival (PFS)"; 2026-12-31
NCT04759586
"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma"; n 244; "Progression-free survival (PFS)"; 2026-12-31
NCT05457257
"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations"; n 43; "Radiological Progression-free Survival - Based on Blinded Independent Central Review (BICR)"; 2026-12-31
NCT00792948
"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia"; n 97; "Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation"; 2027-01-06
NCT03012321
"Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects"; n 70; "Objective Progression Free Survival (PFS)"; 2027-01-16
NCT04862221
"TReatment for ImmUne Mediated PathopHysiology"; n 44; "Survival with native liver (SNL)"; 2027-02
Q9
Which 502 trials of Prednisone posted no result?
Posted no result
502 of 502 completed trials
Registrations
NCT00000596, NCT00000524, NCT00000819, NCT00004430, NCT00004686 and NCT00001615, and 496 more
Completion dates
oldest 1983-01; newest 2024-08-29
Show the evidence
Trial
NCT00000596
1983-01
NCT00000524
1994-03
NCT00000819
1996-09
NCT00004430
1998-09
NCT00004686
1999-09
NCT00001615
2000-05
14 further recorded trials
NCT00004436
2000-06
NCT00003584
2000-12
NCT00002576
2001-01
NCT00518375
2001-05
NCT00000363
2001-06
NCT00002714
2001-09
NCT00518271
2002-06
NCT00057421
2002-09
NCT00004232
2002-10
NCT00018954
2002-10
NCT00268515
2003-03
NCT00004112
2003-03-01
NCT00000421
2003-08
NCT00003490
2003-08
Q10
At the median, Prednisone's trials enrolled 71 people — anything larger?
Median enrolment
71
Largest enrolment
6000000
Registered trials counted
2082
Q11
What do 22755 spontaneous reports say about Prednisone — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Prednisone appears in spontaneous reports to regulators. Across the 9 most-reported reaction terms, 22755 reaction mentions were counted: febrile neutropenia 4657; rheumatoid arthritis 4261; pemphigus 2586; systemic lupus erythematosus 2584. open-targets-adr · CHEMBL635 · 2026-06-24
fasting and exercise are named in Prednisone's label sentences: "Healthy subjects (n = 36) were randomized to abiraterone acetate (single dose, 1000 mg) + low-fat meal, + high-fat meal, and fasted state. mCRPC patients received repeated doses (abiraterone acetate 1000 mg + 5 mg prednisone twice daily; days 1-7) in a modified fasting state followed by abiraterone…" openfda-label+europepmc · 2015-07-23
2 recorded statements; fasting, exercise
Show the evidence
fasting
Healthy subjects (n = 36) were randomized to abiraterone acetate (single dose, 1000 mg) + low-fat meal, + high-fat meal, and fasted state. mCRPC patients received repeated doses (abiraterone acetate 1000 mg + 5 mg prednisone twice daily; days 1-7) in a modified fasting state followed by abiraterone acetate plus prednisone within 0.5 hours post-low-fat (n = 6) or high-fat meal (n = 18; days 8-14).
exercise
We aimed to assess the time to spirometric and exercise responses in stable COPD patients undergoing an oral corticosteroid trial.
recorded 2015-07-23 · last checked 2026-09-04
Q13
What is recorded about Prednisone and NAD+?
"The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including <i>Nampt</i> and <i>Ppargc1a</i> [peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α)]." — where Prednisone and NAD+ appear together. Europe PMC · pathway abstract search · 2024-07-01
"The light-phase prednisone pulse promoted BMAL1-dependent glucocorticoid receptor recruitment on noncanonical targets, including <i>Nampt</i> and <i>Ppargc1a</i> [peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α)]."
mTOR
PMID 37759585
"Azathioprine, mycophenolate and prednisone are associated with lipogenesis. mTOR inhibitors (rapamycin) are used to decrease doses of atherogenic agents used for immunosuppression."
PMID 39011916
"The post-organ transplant immunosuppressive therapy includes the administration of tacrolimus (Tac) or cyclosporine (CsA), along with antimetabolites (Antim) or mTOR inhibitors, with or without prednisone."
PMID 38252908
"After cross-taper to a mammalian target of rapamycin (mTOR) inhibitor and pulsed dose corticosteroids (prednisone 40 mg once daily, the day before and on days 1-3 of each cycle, followed by 20 mg once daily on days 4-6, then 10 mg once daily until the day before each subsequent cycle), patients received cemiplimab 350 mg intravenously once every 3 weeks for up to 2 years and were assessed for…"
recorded 2024-07-01 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 10 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.